BIOMARIN PHARMACEUTICAL INC Operating Lease, Payments
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Operating Lease, Payments of $9.34 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC operating lease, payments for the quarter ending 2020-12-31 was $3.53M, a 55.81% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC operating lease, payments for the quarter ending 2020-09-30 was $3.29M, a 49.37% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC operating lease, payments for the quarter ending 2020-06-30 was $2.27M, a 7.58% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC operating lease, payments for the quarter ending 2020-03-31 was $1.44M, a 10.00% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC operating lease, payments for fiscal 2025 was $9.34M, a 30.22% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC operating lease, payments for fiscal 2024 was $13.39M, a 34.15% increase from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC operating lease, payments for fiscal 2023 was $9.98M, a 7.25% decline from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC operating lease, payments for fiscal 2022 was $10.76M, a 0.90% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $9.34M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $13.39M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $9.98M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $10.76M 10-K · filed 2024-02-26 | |||
| 2021-12-31 | $10.66M 10-K · filed 2023-02-27 | |||
| 2020-12-31 | $3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $6.82M derived: sum of 2 quarters · filed 2022-02-25 | $9.10M derived: sum of 3 quarters · filed 2022-02-25 | $10.54M 10-K · filed 2022-02-25 |
| 2020-09-30 | $3.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $5.57M derived: sum of 2 quarters · filed 2020-11-06 | $7.01M 10-Q · filed 2020-11-06 | $9.27M derived: sum of 4 quarters · filed 2021-02-26 |
| 2020-06-30 | $2.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $3.71M 10-Q · filed 2020-08-05 | $5.98M derived: sum of 3 quarters · filed 2021-02-26 | $8.18M derived: sum of 4 quarters · filed 2021-02-26 |
| 2020-03-31 | $1.44M 10-Q · filed 2020-05-01 | $3.71M derived: sum of 2 quarters · filed 2021-02-26 | $5.91M derived: sum of 3 quarters · filed 2021-02-26 | $8.02M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $4.47M derived: sum of 2 quarters · filed 2021-02-26 | $6.58M derived: sum of 3 quarters · filed 2021-02-26 | $8.18M 10-K · filed 2021-02-26 |
| 2019-09-30 | $2.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $4.32M derived: sum of 2 quarters · filed 2020-11-06 | $5.92M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $2.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $3.71M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $1.60M 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |